Purpose The cure rate in Hodgkin lymphoma is high, but the response along with treatment is still unpredictable and highly variable among patients. Detecting those patients who do not respond to treatment at early stages could bring improvements in their treatment. This research tries to identify the main biological prognostic variables currently gathered at diagnosis and design a simple machine learning methodology to help physicians improve the treatment response assessment. Methods We carried out a retrospective analysis of the response to treatment of a cohort of 263 Caucasians who were diagnosed with Hodgkin lymphoma in Asturias (Spain). For that purpose, we used a list of 35 clinical and biological variables that are currently measured at diagnosis before any treatment begins. To establish the list of most discriminatory prognostic variables for treatment response, we designed a machine learning approach based on two different feature selection methods (Fisher's ratio and maximum percentile distance) and backwards recursive feature elimination using a nearest-neighbor classifier (k-NN). The weights of the k-NN classifier were optimized using different terms of the confusion matrix (true-and false-positive rates) to minimize risk in the decisions. Results and conclusions We found that the optimum strategy to predict treatment response in Hodgkin lymphoma consists in solving two different binary classification problems, discriminating first if the patient is in progressive disease; if not, then discerning among complete and partial remission. Serum ferritin turned to be the most discriminatory variable in predicting treatment response, followed by alanine aminotransferase and alkaline phosphatase. The importance of these prognostic variables suggests a close relationship between inflammation, iron overload, liver damage and the extension of the disease. 
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Purpose The cure rate in Hodgkin lymphoma is high, but the response along with treatment is still unpredictable and highly variable among patients. Detecting those patients who do not respond to treatment at early stages could bring improvements in their treatment. This research tries to identify the main biological prognostic variables currently gathered at diagnosis and design a simple machine learning methodology to help physicians improve the treatment response assessment.
Methods We carried out a retrospective analysis of the response to treatment of a cohort of 263 Caucasians who were diagnosed with Hodgkin lymphoma in Asturias (Spain). For that purpose, we used a list of 35 clinical and biological variables that are currently measured at diagnosis before any treatment begins. To establish the list of most discriminatory prognostic variables for treatment response, we designed a machine learning approach based on two different feature selection methods (Fisher's ratio and maximum percentile distance) and backwards recursive feature elimination using a nearest-neighbor classifier (k-NN). The weights of the k-NN classifier were optimized using different terms of the confusion matrix (true-and false-positive rates) to minimize risk in the decisions.
Results and conclusions We found that the optimum strategy to predict treatment response in Hodgkin lymphoma consists in solving two different binary classification problems, discriminating first if the patient is in progressive disease; if not, then discerning among complete and partial remission. Serum ferritin turned to be the most discriminatory variable in predicting treatment response, followed by alanine aminotransferase and alkaline phosphatase. The importance of these prognostic variables suggests a close relationship between inflammation, iron overload, liver damage and the extension of the disease. the presence of tumor-infiltrating lymphocytes is a negative prognostic factor for survival in these patients [1] . This kind of cancer is most commonly diagnosed in young adults between the ages of 15 and 35 years and in older adults over 50 years. The cure rate in HL patients is high, but the response along the treatment is still unpredictable and varies from patient to patient. Besides, a small minority is resistant or relapses before treatment. Detecting those patients with a poor prognosis at early stages (diagnosis) could bring improvements in their treatment and prognosis.
There was an international effort to identify the prognostic factors to accurately predict the development and treatment of HL, mainly in patients with advanced stage. The adverse prognostic factors identified were: male older than 45 years, stage IV disease, hemoglobin lower than 10.5 g/dl, lymphocyte count lower than 600/ll (or less than 8 %), albumin lower than 4.0 g/dl and white blood count greater than 15,000/ll [2, 3] . Other studies also took into account mixed cellularity or lymphocyte-depleted histologies, the presence of B symptoms or high erythrocyte sedimentation rate and bulky disease as adverse prognostic factors [4, 5] . Moreover, disease extensions measured by computed tomography (CT) and early response to treatment measured by positron emission tomography (PET) have demonstrated a powerful prognostic ability [6, 7] .
Several research works highlighted the importance of the identification of prognostic variables to predict patients who will suffer relapse and the adaptation of treatments to individual risks [8] [9] [10] [11] . Particularly, the result of treatment optimization provoked some criteria modification, with the disappearance of some factors that were considered to be of poor prognosis and with the proposal of new ones that allowed establishing groups with differing risks of relapse and different treatments.
In this manuscript, we inferred prognostic variables for HL treatment response using clinical data and machine learning techniques in a retrospective study of a cohort of 263 Caucasians. For this purpose, we designed a methodology to find the shortest list of clinical variables providing the highest predictive accuracy for Hodgkin lymphoma first-line treatment response (at diagnosis). We found that the best way of addressing this problem is to proceed in two steps: comparing first the complete/partial remission hypothesis against progressive disease hypothesis, and secondly differentiating between complete and partial remission in case it proceeds. Serum ferritin (SF) turned to be the most important prognostic variable, achieving cross-validation predictive accuracies higher than 90 %. Ferritin concentrations increase drastically in the presence of an infection or cancer [12] . Our study also showed the importance of alanine aminotransferase (ALT) and alkaline phosphatase (ALP). The normal ranges for these three prognostic factors are provided in Table  S1 (see Supplementary Material). The importance of these variables in the treatment response suggests a close relationship to iron overload, liver damage and bone affection. An adequate staging of newly diagnosed patients using this methodology will enable optimal treatment planning, which is particularly important in health care to find an optimum balance between treatment efficacy and drug toxicity.
Methods
The present research work is a retrospective study of a cohort of 263 Caucasians who were diagnosed with classical Hodgkin lymphoma in Asturias (Spain) and enrolled in this study between 2002 and 2012. This study was approved by the institutional review boards of the different hospitals involved and performed in accordance with the Helsinki Declaration of 1975. Besides, this study was approved by the Ethics Committee of the Principado de Asturias (date: 17th of January; Project 6th number 13).
Staging definitions from the German Hodgkin Study Group (GHSG) were evaluated in this analysis. All patients were treated with the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen: 125 patients (47 %) received involved field radiotherapy, 91 with early stage and 34 with advanced stage disease. Response to therapy was evaluated by physical and radiographic evaluation, including computed tomography (CT) and the follow-up of the patients. In the last 5 years, PET scan was also included to assess treatment response. The treatment response was divided into three categories according to international standards [13] : 237 of the patients were in complete remission (CR), 17 in partial remission (PR) and only in 9 cases the disease progressed without any relevant change. This last category was named as progressive disease (PD). Table 1 describes the main characteristics of the patients: age, sex, stage at diagnosis, percentage of early favorable and early unfavorable and percentage of advanced disease depending on Hasenclever Prognostic Score.
Progression-free survival (PFS) was calculated from the date of diagnosis to the date of progression, relapse or death by of any cause. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause or last follow-up. Overall and progression-free survival distribution curves were estimated using the product-limit method of Kaplan-Meier. The median PFS and OS for the entire group were, respectively, 150 and 160 months. The probabilities of PFS and OS at 7 years were 57 and 76 %, correspondingly.
Thirty-five clinical and biological variables were measured at diagnosis and before treatment. These variables were classified into five groups: biochemical, immunohistochemical, Hodgkin lymphoma specific, treatment specific and host information. Table 2 shows the description of all these variables, boldfacing those that take discrete predefined values. Most of the variables had a sampling frequency higher than 90 %. However, others were scarcely sampled, such as CRP (14 %), immunoglobulins and Ki67 (20 %). The need of imputing/filtering those variables has turned out to be a very important step in the modeling process.
The problem addressed in this manuscript consists in building an efficient and simple machine methodology to predict HL first-line treatment response with the highest predictive accuracy, and at the same time minimizing risk in the decisions. For that purpose we have used the response criteria defined by Cheson et al. [13] . Patients were divided into three categories: complete remission (CR), defined as the disappearance of all evidence of disease; partial remission (PR) defined as regression of measurable disease and no new sites; and progressive disease (PD) defined as any new lesion or increase by 50 % of previously involved sites. Four different classification problems were performed to find the optimum way of separating these three classes.
The machine learning methodology is explained in Appendix 1 (see Supplementary Material) and is composed of three main steps: (1) pre-processing, (2) feature selection and (3) k-NN design and risk analysis. Basically, the learning method consists, according to the parsimony principle, in finding the shortest subset of most discriminatory clinical variables (also called the reduced base of prognostic variables) to predict treatment response in HL patients. The clinical and biological variables are first ranked according to two different filter methods: Fisher's ratio (FR) and maximum percentile distance (MPD). In a second step, the predictive accuracy of the different ranked lists of prognostic variables is established by leave-one-out-crossvalidation (LOOCV) experiment using a simple k-nearestneighbor (k-NN) classifier (Appendix 1 in Supplementary Material). This methodology has been successfully applied to predict risk of radiotherapy-related fatigue in prostate cancer patients using high-dimensional expression data [14] . In this case, the challenge is not related to the dimension of the dataset, but to the heterogeneous degree of sampling of the different clinical variables. Besides, in this case the methodology incorporates the weight optimization of the k-NN classifier according to the receiver operating characteristic (ROC) curve to improve risk decision-making, that is, to provide a very high predictive accuracy with an optimum balance between the different rates of the confusion matrix (the true-positive and false-positive rates defining the corresponding ROC curve). Figure 1 shows a flow diagram explaining the methodology.
Finally, we would like to point out that the aim of this work is not to numerically compare different machine learning methods, but to introduce simple algorithms to select the shortest list of prognostic variables that could be easily interpreted by medical doctors, to improve the patient prognostic in HL treatment response, with its corresponding risk assessment. Particularly, we tried to avoid the use of black boxes that provide estimations without medical doctors' understanding. As a matter of fact, this methodology can be easily implemented in any platform such as a spreadsheet (see Supplementary Material-HL treatementResponse_Predic-tor.xls-, and the corresponding explanation provided in Appendix 2). That said, the classifier that is proposed in this paper outperformed other more sophisticated classifiers that are proposed in the machine learning literature, highlighting the importance of selecting the correct prognostic variables.
Results
Treatment response in HL is a difficult prediction problem. Aside from plasma EBV DNA [15] , there is no predictive biomarker to predict the patient's response to the corresponding treatment with a reliable accuracy. This classification problem is intrinsically highly unbalanced, mainly due to the discrete sampling of the samples (number of patients) and also because a high percentage of the patients are cured from this kind of malignancy.
The first modeling decision was to transform the analysis of treatment response into a binary classification problem (two-class problem) that admits a more reliable and stable solution than the corresponding value regression problem, that is, it is easier to predict if a patient is in complete or partial remission than predicting the value of the biological variables related to this fact. Besides, the prediction in binary classification problems allows for risk assessment through the analysis of the confusion matrix and the receiving operating characteristic (ROC) curve. The confusion matrix consists of four different groups: true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN), whose definition depends on how the classification problem has been set up. From the confusion These rates could be used by the physicians in their decision-making process. A perfect classifier would have 100 % sensitivity and specificity.
The following comparisons were performed: Comments for the prognostic variables in comparisons 1 and 3 are given in Appendix 3 (see Supplementary Material), since we have obtained worse results. The most effective comparison was the second one and it was composed of two main steps. In the first step (2.1 CR?PR vs. PD), we established the differences between patients who experienced partial or complete remission (CR?PR, positive class) from those in which the disease progressed without any relevant change (PD, negative class). Then, a second comparison (2.2 CR vs. PR) was used to establish the differences between CR (positive class) and PR (negative class) patients.
The best result was obtained by filtering out those variables having a sampling frequency lower than 30 %, and imputing the rest. Besides, MPD (maximum percentile distance) provided the shortest list of variables with the highest predictive accuracy. Table 3 shows the confusion matrix rates (TPR, TNR, FPR, FNR) for all the binary classifications (comparisons 1 and 2), together with the false discovery rate (FDR) and the LOOCV predictive accuracy (ACC). No weight optimization was performed in this case, that is, the weights corresponded to the inverse of the prior variability of the prognostic variables (see Appendix 1 Supplementary Material). Table 4 shows the mean values of the three prognostic variables for the different groups of the confusion matrix and the weights (W) used to define the distance criterion in the nearest-neighbor classifier. The algorithm used for all the comparisons was the same: filtering 30 % of sampling frequency, imputing and MPD as feature selection method. Rate is the maximum percentile distance rate, TPR true-positive rate, TNR true-negative rate, FPR false-positive rate, FNR false-negative rate and Acc final accuracy of the prediction. Signs (?) and (-) represent the positive and negatives groups, respectively Signs (?) and (-) represent positive and negatives groups, respectively. Boldfaces indicate the highest value for each prognostic variable. Normal bounds for the decision correspond to the TP and TN groups. W b are the weights used in the classifier for data variability normalization (before weight optimization)
Comparison 2.1: CR1PR vs. PD
In this comparison serum ferritin was the single selected prognostic variable (using MPD as feature selection) with a predictive accuracy of 95.82 %. The SF mean value in the TN group (3288 ng/mL) was even higher than in the previous comparison, the SF value in the TP group being 266 ng/mL. Therefore, patients with progressive disease show a very clear inflammatory behavior as shown by the SF value at diagnosis. The TPR of this comparison is very high (98.43 %), and the TNR is higher than in the comparison 1 (22.22 %). The TP and FP maximum and minimum SF values are closer to normal SF values (see Table  S1 of Supplementary Material). Conversely, the TN and FN corresponding SF signatures are extreme values.
Comparison 2.2: CR vs. PR
The best subset of prognostic variables for this case was found by MPD and was composed of SF, ALT and ALP, providing 92 % of LOOCV predictive accuracy. The TPR is very high (97.89 %) and the TNR is quite low (11.76 %), that is, the difference between partial and complete remission is very hard to tell, and the classifier tends to assign the complete remission class in most of the cases.
There is a big gap between SF mean levels of both TP (249 ng/mL) and TN (2401 ng/mL) groups. Moreover, FP (405 ng/mL) and FN (2131 ng/mL) mean SF values are similar to the mean SF values of the TN and TP groups, respectively. The same happens with ALP; there is also a big difference between TP (116.8 U/L) and TN (376 U/L) values. The mean values in the FP (163.5 U/L) and FN (608.4 U/L) groups are also close to the TP and TN groups, which make those samples very difficult to correctly predict using this k-NN classifier. SF and ALP have higher mean values in the TN group than in the TP group. However, in the case of ALT, the mean value in the TP group (23.7 U/L) is higher than in the TN group (18 U/L). Moreover, the difference between these two groups is very low. The ALT mean value in the FN group (74.4 U/L) is closer to the TP group, instead of being closer to the TN group, as it should be expected. This is due to the presence of some PR patients with anomalously large ALT values.
k-NN weight optimization
Optimization of the weights of the k-NN classifier via Particle Swarm Optimization (PSO) was performed to improve the true negative rate (or specifity), that is, increasing TNR while the overall accuracy is also improved (TPR is not affected). Details about PSO are given in Appendix 1 (see Supplementary Material). Table 5 shows the TPR, TNR, FPR, FNR, FDR and predictive accuracy (Acc) obtained after weight optimization. TN rates were improved around 10 % in comparisons 2.1, while in comparison 2.2 TP rate was improved around 1 %. The overall accuracy was improved in all the cases around 1 %. Table 6 shows the mean values for TP, TN, FP, FN and the optimized weights for the prognostic variables (x a ). It can be observed that values of the weights increased after optimization for all the prognostic variables. Therefore, it is possible to improve the quality of the prediction and minimize risk on the decisions, by optimizing the weights that are initially provided by the distance criterion.
Conclusions
In this paper we presented an optimum strategy to predict treatment response in HL. Three main discriminatory prognostic variables were used in this analysis: serum ferritin, ALT and ALP.
Serum ferritin has been frequently used as a surrogate marker for systemic iron stores, but may be also elevated in specific circumstances without excess iron stores, such as in inflammation, correlating closely to the activity of malignant lymphomas. Serum ferritin levels have been reported to be elevated in HL patients, in particular in Rate is the maximum percentile distance rate, TPR true-positive rate, TNR true-negative rate, FPR false-positive rate, FNR false-negative rate and Acc final accuracy of the prediction. Signs (?) and (-) represent the positive and negatives groups, respectively advanced stages and during disease progression [16, 17] . Moreover, it has been proposed that the release of IL-6 stimulates the overproduction of hepcidin in the liver, which correlates with the iron restriction and contributes to anemia in HL [18] . In addition, the abundant microenvironment surrounding the neoplastic Hodgkin's and ReedSternberg cells may contribute to alterations in iron metabolism [19] . Besides, serum ferritin concentration closely follows the activity of malignant lymphomas [20] . Another research work [21] has shown that levels of serum ferritin higher than 500 ng/mL are an important marker for predicting poor survival outcomes for non-Hodgkin lymphoma. Nevertheless, and to our knowledge, serum ferritin levels have not been yet related to the treatment response of HL patients. Serum activity levels of ALT enzyme are routinely used as a biomarker of liver injury caused by drug toxicity, infection, alcohol and steatosis. ALT plays a key role in the intermediary metabolism of glucose and amino acids and also participates in cellular nitrogen metabolism and liver gluconeogenesis. This cytosolic enzyme catalyzes the transfer of the a-amino group from alanine to a-ketoglutaric acid. Serum levels of ALT are normally low (10-40 U/L), but any type of liver cell injury may modestly increase the ALT levels. Levels greater than 500 U/L occur most often in people with hepatic diseases, such as viral hepatitis, ischemic liver injury (shock liver), toxin-induced liver damage and tumor infiltration of liver. Despite the association between greatly elevated ALT levels and hepatocellular diseases, the levels of ALT do not correlate with the extent of liver cell damage [22] .
The alkaline phosphatase test (ALP) is used to detect liver disease or bone disorders. In conditions affecting the liver, damaged liver cells release increased amounts of ALP into the blood. Further, any condition that affects bone growth or causes increased activity of bone cells can affect ALP levels in the blood. In non-Hodgkin lymphomas, ALP is increased in patients with bone marrow disorders [23] , thus reaching stage IV and worse prognosis. A recent study suggests that ALP together with gammaglutamyl transferase and albumin may define advanced stages of HL [24] . Moreover, bone affection is also associated with a high progression degree (HR: 1.96) [25] . However, in a patient with fever of unknown origin (FUO), highly elevated alkaline phosphatase and normal/slightly elevated serum transaminase levels suggest the possibility of lymphoma [26] [27] [28] .
Overall, the results of this study show that the combined use of these prognostic variables, SF, ALT and ALP, in a simple classifier allows predicting first-line treatment response in HL patients with high accuracy and confirms a close relationship between treatment response in HL, inflammation, iron overload and liver and bone damage. Particularly, the combination of feature selection methods (maximum percentile distance), risk assessment analysis (ROC curve) and global optimization (PSO) provides biomarker discovery that is easily implemented in spreadsheet.
To conclude, detecting those HL patients who do not respond to the treatment at early stages may help improve their treatment. This study proposed a new prognostic analysis method, based on mathematical models that identify three simple prognostic variables currently gathered at diagnosis that may help detect with high accuracy those HL patients with bad prognosis without any additional cost. 
